- This event has passed.
AACR-Lung Cancer Initiative at Johnson & Johnson Stimulating Therapeutic Advances Through Research Training (START) Grant
Dramatic advances made in recent years towards precision medicine initiatives, biomarker and novel target identification, and high-throughput examination of genomic data, have resulted in a trove of valuable data that can inform the development of new therapeutics to combat cancer. However, to effectively harness this wealth of information and advance the discovery and development of new therapies for cancer patients, enhanced collaboration between academia and industry will be needed.
The AACR-Lung Cancer Initiative at Johnson & Johnson Stimulating Therapeutic Advances through Research Training (START) Grants represent an exciting initiative to address the need for promoting and supporting such collaborations. These grants, which will provide support to postdoctoral or clinical research fellows from underrepresented groups (please see eligibility criteria below), combine research experiences in both academic and industry settings, following a research timeline that will be of greatest benefit to the proposed work. The training provided through this grants program will be invaluable to young investigators by providing fellows with a comprehensive research experience that will make them highly desirable to potential employers in either academic research or the pharmaceutical industry.
Each fellowship provides a three-year grant of $225,000 to support the salary and benefits of the fellow while working on a mentored cancer research project. Research proposals may be translational or clinical in nature but must have direct applicability to lung cancer. Proposals focused on mechanisms linking immunogenic cell death pathways to amplification of innate and adaptive immunity, immunobiology of non-small cell lung cancers, and mechanisms of acquired resistance to immunotherapies are highly encouraged. Applicants may spend one year on site at a Johnson & Johnson Enterprise Innovation facility at the discretion of Lung Cancer Initiative at Johnson & Johnson. One of a number of Johnson & Johnson Enterprise Innovation’s locations are possible, at the discretion of Johnson & Johnson. The year at JJEI will be determined on a case-by-case basis and will be at a time agreed upon by the fellow, the academic supervisor, the Johnson & Johnson Enterprise Innovation mentor, and Johnson & Johnson Enterprise Innovation.
APPLY BY AUGUST 18: https://proposalcentral.com/grantopportunities.asp?GMID=39